Organoids are three-dimensional clusters of living cells grown from tissue taken from patients. Unlike conventional cancer cell lines, which can acquire extensive genetic and behavioral changes after prolonged culture, patient-derived organoids are designed to preserve key characteristics of the original tumor. They can reproduce aspects of tumor architecture, genetic variation, cell behavior and treatment response, allowing scientists to investigate cancer biology in a controlled laboratory environment.

The HCMI collection includes organoids derived from pancreatic, breast, endometrial, colorectal, bladder, ovarian, head and neck, and lung cancers, among other malignancies. Scientists at Cold Spring Harbor Laboratory (CSHL) and Northwell Health led one of the largest contributing teams, providing more than 150 models to the international compendium. Collaborators at the University of Verona in Italy and Hubrecht Institute in the Netherlands also played major roles, including the development and distribution of dozens of pancreatic and colorectal cancer models.

The resource goes beyond living organoid cultures. It links many models to matched tissue from the original tumors, detailed clinical information and molecular data, including DNA and RNA sequencing, transcriptomic profiles and epigenetic measurements. Of the 665 models, 522 include comprehensive clinical data, while 153 represent rare cancers. The collection also contains 71 models from participants of non-European ancestry, addressing a long-standing problem in biomedical research: the underrepresentation of diverse patient populations in preclinical studies.

Researchers created 43 models from pediatric or adolescent patients, and approximately 23 percent of successful models came from rare cancer types. This breadth could make the collection especially valuable for studying cancers that are difficult to obtain in sufficient numbers for conventional experiments. Rare tumor subtypes often have few established cell lines and limited clinical trial data, meaning that organoids may provide an important experimental bridge between individual patient samples and broader biological discoveries.

To ensure that the organoids remained faithful to their source tumors, the HCMI teams established standardized production and quality-control procedures. At CSHL’s Genome Center, researchers used cancer hotspot sequencing to monitor key genetic alterations and assess the identity and quality of developing models. Organoids can also be expanded and cryopreserved, enabling laboratories to perform repeated experiments on the same tumor-derived material without requiring a new biopsy or continuously collecting fresh tissue.

The models are already being incorporated into drug-discovery research. Because organoids can be grown in multiwell plates, scientists can expose them to many drugs or drug combinations at different concentrations and measure effects on cell survival, proliferation and morphology. This approach could help identify therapies that are more likely to work against a particular tumor while revealing resistance mechanisms. Researchers emphasize, however, that organoid drug testing is not yet a substitute for clinical trials and must be interpreted alongside patient data and other biological models.

The HCMI organoids have also expanded the Cancer Dependency Map, or DepMap, a major research program designed to identify genetic and molecular vulnerabilities that cancer cells depend on for survival. By testing diverse organoid models, investigators can examine whether a potential dependency is shared across tumors or limited to a particular genetic background, tissue type or patient population. Such information may help researchers prioritize therapeutic targets and develop more precise strategies for tumors that do not respond to existing treatments.

The initiative was built around close coordination between clinical teams, hospital biospecimen repositories and laboratory scientists. Northwell Health, which treats more than 19,000 cancer patients annually, helped provide access to patient samples and established a pipeline connecting clinical care with experimental research. The project’s leaders say that patient consent and participation were fundamental to creating the resource. By making these models and their associated data available worldwide, the HCMI aims to accelerate cancer research, improve the reproducibility of preclinical experiments and move the field closer to personalized treatment decisions.

Subject of Research: Patient-derived organoid models for cancer research, precision medicine and therapeutic discovery

Article Title: A compendium of next-generation patient-derived models for diverse cancers

News Publication Date: 5 August 2026

Web References: Cold Spring Harbor Laboratory: https://www.cshl.edu/ ; Northwell Health: https://www.northwell.edu/ ; Nature article: https://www.nature.com/articles/s41586-026-10843-7

References: Nature, “A compendium of next-generation patient-derived models for diverse cancers.” DOI: 10.1038/s41586-026-10806-y

Image Credits: Hardik Patel/Cold Spring Harbor Laboratory

Keywords: Organoids, cancer research, patient-derived models, personalized medicine, cancer genomics, translational research, transcriptomics, epigenomics, drug screening, tumor biology

“Our rise reflects years of commitment to building a truly comprehensive cancer center where scientific discovery and exceptional patient care advance hand in hand,” said Stephen D. Nimer, M.D., director of Sylvester. He said the center’s multidisciplinary teams are increasingly equipped to deliver experimental therapies and specialized treatments to patients with complex or difficult-to-treat cancers. This model links laboratory research with clinical practice, allowing discoveries in areas such as tumor biology, molecular diagnostics and therapeutic development to move more efficiently toward patient care.

Sylvester is the only National Cancer Institute-designated cancer center in South Florida, a designation that recognizes institutions with substantial research activity, advanced cancer programs and a commitment to reducing the burden of cancer. Its work spans basic science, population research, clinical investigation and direct treatment. This integrated structure is designed to improve the accuracy of diagnosis, identify biological differences between tumors and match patients with therapies that are more precisely suited to the molecular characteristics of their disease.

A central component of that effort is Sylvester’s academic Phase 1 Clinical Trials Program, described as the only program of its kind in South Florida. Phase 1 trials are generally the first studies in which a new drug, biologic therapy or treatment combination is tested in people. Researchers primarily evaluate safety, tolerability, dosage and how the treatment behaves in the body, although early signals of effectiveness may also emerge. For patients whose cancers have resisted standard therapies, these studies can provide access to treatments years before they become broadly available, while generating data needed for later-stage clinical development.

The center’s research capacity expanded substantially with the opening of the 12-story Kenneth C. Griffin Cancer Research Building in 2025. The facility doubled Sylvester’s research space and brought scientists, physicians, clinical investigators and data specialists into closer proximity. Such physical and organizational integration is important in translational medicine, which seeks to convert discoveries from laboratory models into diagnostic tools, clinical trials and treatments. Shared research environments can accelerate the analysis of tumor samples, the testing of candidate therapies and the development of data-driven approaches to predicting treatment response.

Sylvester is also extending cancer research and prevention beyond its main clinical facilities. Its Game Changer mobile program brings cancer screening, education and research opportunities to medically underserved communities across South Florida. Mobile outreach can help reduce barriers related to transportation, geography and access to specialty care, while screening programs may identify disease at earlier and more treatable stages. The center also leads a nationally recognized firefighter cancer initiative focused on research, prevention, screening and advocacy, addressing occupational exposures and other factors that may influence cancer risk in firefighting populations.

Additional programs target cancer survivorship and prevention. An NCI-funded effort is working to strengthen survivorship care through community health centers, where patients may receive long-term monitoring and support closer to home after completing treatment. Sylvester is also advancing lifestyle medicine and research on human papillomavirus-associated cancers. HPV can contribute to the development of several malignancies, including cervical, anal, oropharyngeal and other cancers. Combining vaccination, screening, behavioral interventions and molecular research may help reduce preventable disease and improve outcomes for people already diagnosed.

The latest rankings reflect performance across the wider UHealth system as well. Four additional programs earned national rankings, including ophthalmology, neurology and neurosurgery, geriatrics, and cardiology, heart and vascular surgery. Bascom Palmer Eye Institute retained the nation’s No. 1 position in ophthalmology for the 25th consecutive year. UHealth’s neurology and neurosurgery program ranked No. 14 nationally and includes more than 70 research and clinical faculty working across neurological subspecialties. Five other specialties—urology, diabetes and endocrinology, gastroenterology and gastrointestinal surgery, orthopedics, and pulmonology and lung surgery—received high-performing designations, placing them among the top 10% of hospitals nationwide.

Together, the results point to an expanding health system built around specialized care, research infrastructure and long-term patient management. “We are proud of what these results say about our progress, but our focus remains on what comes next,” said Dipen J. Parekh, M.D., chief executive officer of UHealth. He said the system would continue investing in people, innovation and specialized services. For Sylvester, the national rise is both a measure of recent progress and a sign of the competitive importance of connecting advanced cancer biology, early-phase clinical research, community prevention and comprehensive care within a single academic health system.

Subject of Research: Cancer research, clinical oncology, cancer prevention, Phase 1 clinical trials and translational medicine.

Article Title: Sylvester Cancer Center Rises to No. 23 Nationwide in 2026 U.S. News Rankings

News Publication Date: August 4, 2026

Web References: Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center; Kenneth C. Griffin Cancer Research Building: https://umiamihealth.org/en/locations/sylvester-comprehensive-cancer-center-kenneth-c-griffin-cancer-research-building; UHealth rankings report: https://news.med.miami.edu/uhealth-highest-us-news-hospital-rankings-2026/

References: U.S. News & World Report 2026 Best Hospitals rankings; National Cancer Institute cancer center designation information; Sylvester Comprehensive Cancer Center announcement.

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: Cancer, cancer research, clinical research, oncology, Phase 1 clinical trials, translational medicine, Sylvester Comprehensive Cancer Center, UHealth, University of Miami, National Cancer Institute, cancer prevention, survivorship care

High-grade serous ovarian cancer is a particularly aggressive form of the disease, often diagnosed at advanced stages, resulting in bleak prognoses for patients. Characterized by its propensity for metastasis, especially to the omentum—a fatty tissue that drapes over the abdominal organs—this subtype of ovarian cancer poses significant treatment challenges. Gao et al. have delved into the molecular underpinnings of this form of cancer, focusing on how LAPTM5 contributes to this metastatic progression.

The study outlines how LAPTM5 enhances the capacity of cancer cells to undergo epithelial-mesenchymal transition (EMT), a crucial process where epithelial cells lose their adhesive properties and gain migratory abilities. This transition is pivotal in the context of metastasis, allowing cells to invade surrounding tissues and eventually disseminate throughout the body. The role of the TGF-β/Smad signaling pathway in regulating EMT is well-established; however, Gao and colleagues provide new insights into the upstream activator, LAPTM5, which appears to interact with this pathway to orchestrate complex cellular responses.

The researchers utilized both in vitro and in vivo models to dissect the functionalities of LAPTM5. Their compelling data reveal that knocking down LAPTM5 expression leads to a significant reduction in migratory capabilities of HGSOC cells. This finding suggests that targeting LAPTM5 may hinder the invasive behavior of these cancerous cells, presenting a potential avenue for therapeutic intervention.

In addition to shedding light on how LAPTM5 facilitates EMT, the study also explores the downstream effects of this signaling cascade. The TGF-β/Smad pathway, when activated, promotes the expression of several key factors involved in cell motility and invasion. It appears that LAPTM5 acts as a molecular switch, heightening the responsiveness of ovarian cancer cells to TGF-β signaling. This enhanced plasticity might serve as a double-edged sword—while it allows the cancer cells to invade new territories, it also could make them more adaptable to therapeutic pressures, contributing to treatment resistance.

Furthermore, the intricate relationship between LAPTM5 and the tumor microenvironment cannot be overlooked. The research indicates that the expression levels of LAPTM5 correlate with fibroblast activation and the secretion of various cytokines, creating a rich milieu that fosters metastatic spread. This interaction emphasizes the importance of not viewing cancer cells in isolation but rather in the context of their surrounding environment, which greatly influences their behavior.

The implications of these findings extend beyond understanding the biology of HGSOC; they highlight the need for developing targeted therapies that could inhibit LAPTM5 or disrupt its interaction with the TGF-β/Smad pathway. Such innovative strategies could potentially halt or even reverse the metastatic spread of ovarian cancer, offering hope to patients facing this dire diagnosis.

Moreover, the employment of novel inhibitors specifically targeting LAPTM5 presents an exciting frontier in the management of high-grade serous ovarian cancer. As the field moves towards more personalized treatment approaches, exploits in genetic and molecular profiling could offer insights into who might benefit most from such therapies. The study by Gao et al. serves as a clarion call to focus research efforts on less conventional targets in the ongoing battle against cancer.

In conclusion, the intricate dance between LAPTM5 and TGF-β/Smad-mediated signaling pathways opens new avenues for exploration in ovarian cancer research. By unveiling the mechanisms through which LAPTM5 drives omental metastasis, Gao et al. lay the groundwork for future studies aiming to design interventions that can stifle the spread of this malignancy. As researchers continue to unravel the complexities of ovarian cancer, it is hopeful that these advancements will lead to breakthrough therapies that could markedly improve patient outcomes.

There remains much to learn, and as we progress in this field, collaborative efforts among researchers, clinicians, and pharmaceutical developers will play a vital role in translating these findings into clinical practice. The emergence of LAPTM5 as a central player in cancer metastasis underscores the urgency of novel therapeutic strategies in combating high-grade serous ovarian cancer, potentially changing the narrative for women affected by this formidable adversary.

Subject of Research: Ovarian Cancer Metastasis
Article Title: LAPTM5 drives omental metastasis in high-grade serous ovarian cancer via TGF-β/Smad-mediated epithelial plasticity
Article References:
Gao, Y., Li, J., Han, X. et al. LAPTM5 drives omental metastasis in high-grade serous ovarian cancer via TGF-β/Smad-mediated epithelial plasticity. J Transl Med 23, 1431 (2025). https://doi.org/10.1186/s12967-025-07319-z
Image Credits: AI Generated
DOI: https://doi.org/10.1186/s12967-025-07319-z
Keywords: Ovarian Cancer, LAPTM5, Metastasis, TGF-β, EMT, High-Grade Serous Ovarian Cancer.

Ovarian cancer remains one of the deadliest forms of cancer among women, largely due to its late-stage diagnosis and the complexity of its underlying biology. Traditional therapies have been met with limited success, emphasizing the need for innovative strategies that target the molecular intricacies of this disease. The study in focus sheds light on the inhibitory mechanisms of ferroptosis, a form of regulated cell death, highlighting how the interaction between HCP5 and polypyrimidine tract binding protein 1 (PTBP1) serves to impede this process, thereby promoting tumor survival and growth.

Ferroptosis has emerged in recent years as a distinct form of cell death characterized by iron-dependent lipid peroxidation. This type of cell death contrasts sharply with conventional apoptotic pathways, offering unique opportunities for therapeutic exploitation. The capacity to manipulate ferroptosis could fundamentally alter the treatment landscape for various cancers, presenting an emerging frontier in oncological research. Investigating the relationship between non-coding RNAs and ferroptosis could offer critical insights into tumor aggressiveness and resistance mechanisms.

The research team’s focus on the non-coding RNA HCP5 positions this molecule at the forefront of cancer biology. Long non-coding RNAs, once thought to be mere transcriptional noise, have now been implicated in a multitude of cellular processes including gene regulation, chromatin remodeling, and cell signaling. The findings from Chen and colleagues indicate that HCP5 is upregulated in ovarian cancer tissues, suggesting that it may play a pivotal role in the malignancy’s pathogenesis.

Through a series of innovative experimental approaches, the study establishes a compelling connection between HCP5 and PTBP1, a factor known for its roles in mRNA splicing and stability. Their interaction not only underscores the complexity of RNA biology but also hints at the potential for targeting these molecular interactions therapeutically. By inhibiting this pair’s function, there may be opportunities to enhance ferroptosis in ovarian cancer cells, thereby curtailing tumor growth.

Moreover, the implications of this study extend beyond ovarian cancer, as the dysregulation of ferroptosis has been implicated in several other malignancies. This research invites further inquiry into the broader role of long non-coding RNAs and their interactions with critical proteins in the regulation of cell death pathways. Understanding these relationships could foster the development of novel RNA-centric therapeutic strategies that target multiple dimensions of cancer biology.

In the context of translational research, the potential of harnessing long non-coding RNAs like HCP5 in clinical settings could redefine treatment protocols for ovarian and other cancers. As the scientific community continues to uncover the molecular underpinnings of these complex diseases, integrating these insights into therapeutic frameworks will be critical. The challenge remains to translate these findings from fundamental research into safe and effective clinical interventions.

Furthermore, the pathways involved in ferroptosis present unique challenges and opportunities. The possibility of inducing ferroptosis in cancer cells opens a new therapeutic window, particularly in cases where traditional therapies have failed. By elucidating the mechanisms through which HCP5 influences ferroptosis, this study may pave the way for the design of combination therapies that could circumvent resistance mechanisms commonly seen with standard treatments.

As the insights garnered from the Chen et al. study ripple through the oncology research community, it becomes increasingly clear that a multidisciplinary approach is essential for driving innovation in cancer therapy. Collaborative efforts that bridge molecular biology, bioinformatics, and clinical practice will be crucial in translating these findings into effective treatments for patients battling ovarian cancer.

In conclusion, this groundbreaking study not only sheds light on the pivotal role of HCP5 in ovarian cancer progression but also underscores the importance of investigating novel molecular targets in the fight against cancer. The revelation that long non-coding RNAs can significantly influence cell survival through mechanisms like ferroptosis could redefine our approach to cancer therapy, fostering the hope of more effective treatment options in the years to come. As research evolves, it will be vital to maintain a focus on the implications of these findings in both basic and clinical settings, ultimately enhancing our ability to manage and treat this formidable disease.

This research underscores the significance of innovative discoveries in the realm of cancer biology, illuminating paths previously obscured by conventional understanding. Emerging studies on the interplay between non-coding RNAs and fundamental cell death mechanisms provide a crucial scaffold upon which future therapeutic strategies can be built. With continued research and collaboration, the next breakthrough in cancer treatment may be just around the corner.

Subject of Research: Long non-coding RNA HCP5 in ovarian cancer progression

Article Title: Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.

Article References:

Chen, X., Ren, Q., Zheng, X. et al. Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.
J Ovarian Res 18, 271 (2025). https://doi.org/10.1186/s13048-025-01861-6

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01861-6

Keywords: Long non-coding RNA, HCP5, ovarian cancer, ferroptosis, PTBP1, tumor progression, cancer therapy.